News >

Olaparib Expands Options in Metastatic Pancreatic Cancer

Jessica Hergert
Published: Tuesday, Jan 07, 2020

A. Craig Lockhart, MD, MHS, a professor and associate director for Regional and Strategic Clinical Research Affiliations, Sylvester Comprehensive Cancer Center, University of Miami Health System

A. Craig Lockhart, MD, MHS

The metastatic pancreatic cancer paradigm has expanded to include frontline maintenance therapy with the PARP inhibitor olaparib (Lynparza), as it recently received the green light from the FDA with a December 2019 approval.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication